The Best of the AACR Journals collection 2016 highlights the most-cited articles published in 2015 across the AACR journals. Three VPC scientists, Drs Chi, Collins & Gleave, are included in this prestigious group for their articles “Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer” in Clinical Cancer Research (Chi and Collins) and “Anticancer Activity of a…
Read More
Carbonic anhydrase IX (CAIX) is a hypoxia inducible factor 1-induced, cell surface pH regulating enzyme with an established role in tumor progression and clinical outcome. However, the molecular basis of CAIX-mediated tumor progression remains unclear. Here, we have utilized proximity dependent biotinylation (BioID) to map the CAIX ‘interactome’ in breast cancer cells in order to identify physiologically relevant CAIX-associating proteins…
Read More

REVIEW: Genes and Molecular Pathways Underpinning Ciliopathies

Motile and non-motile (primary) cilia are nearly ubiquitous cellular organelles. The dysfunction of cilia causes diseases known as ciliopathies. The number of reported ciliopathies (currently 35) is increasing, as is the number of established (187) and candidate (241) ciliopathy-associated genes. The characterization of ciliopathy-associated proteins and phenotypes has improved our knowledge of ciliary functions. In particular, investigating ciliopathies has helped…
Read More
This week, the Michael Smith Foundation for Health Research announced the recipients of their Scholar and Research Trainee Awards. These grants go towards furthering the MSFHR’s mission to fund innovative and promising research in British Columbia. Many ICORDians have benefited from this support. This year, one Investigator and five postdocs from ICORD have won MSFHR Awards! Dr. Heather Gainforth, an ICORD Investigator…
Read More
Our well-powered study had two major findings, both of which have profound implications across multiple fields.  First, we found that mild life-long reduction in circulating insulin improves glucose homeostasis and insulin sensitivity in old mice. This demonstrates that at least some age-dependent insulin resistance is caused by the hypersecretion of insulin itself. This simple observation is the first clear evidence of causality to one of the most important chicken-and-egg debates in the metabolism field...
Read More
The formation of blood clots is mediated by an intricate and dynamic interplay between platelets, blood clotting proteins, and small molecules. While rapid clot formation is essential for stopping blood loss at wound sites, uncontrolled blood clotting can evolve into thrombosis, causing organ failure and even death if left untreated. In order to better understand the underlying complex biochemistry of…
Read More

Zucara Therapeutics Announces New Board Member

Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, is pleased to announce that Dr. Claude Piché has joined its Board of Directors. As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the company from start up through to completion of phase III clinical studies, ultimately…
Read More
Mutations in genes encoding epigenetic regulators as well as mutations in the histones they modify are increasingly recognized as drivers of transformation. Mutations in DNA methylation regulators have been identified as frequent early events in the generation of acute myeloid leukemia (AML) clones and are also found at high frequency in expanded, but apparently otherwise normal clones of blood cells in older people.
Read More

MSFHR Funds 53 Exceptional Health Researchers

MSFHR has announced 53 funding-award recipients (20 Scholars and 33 Research Trainees) from across the lower mainland, Prince George, Kelowna and Victoria. These award recipients, selected from a highly competitive pool of applicants, represent a bright future for health research in British Columbia. “We are thrilled that with the support of our award partners we are able to offer funding…
Read More

InMed Signs R&D Agreement with ATERA

 InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce it has entered into a research and development collaboration with ATERA SAS of France, a leading tissue engineering company specializing in the development of advanced human tissue models.  Under the terms of the agreement, ATERA will develop 3D human skin models of…
Read More